Journal of Clinical Oncology, Vol 9, 2225-2232, Copyright © 1991 by American Society of Clinical Oncology

ARTICLES

Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials

JA O'Shaughnessy, RE Wittes, G Burke, MA Friedman, JR Johnson, JE Niederhuber, ML Rothenberg, J Woodcock, BA Chabner and R Temple
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.

Expeditious clinical development and approval of new drugs that are beneficial to patients are matters of high priority. There has been a great deal of discussion within the oncology community about what should constitute evidence of effectiveness of new anticancer agents for purposes of drug approval. This commentary is intended to illustrate a variety of end points that can lead to approval of new anticancer agents for specific clinical situations. Although the ultimate hope of antineoplastic therapy is prolongation of life, there are other effects of anticancer drugs that constitute clear clinical benefit and represent evidence of effectiveness. The guiding principle is that the beneficial effects obtained from a new drug should sufficiently outweigh the adverse effects such that the potential risk:benefit ratio achieved by an individual patient is favorable. The assessment of a new drug should flexibly evaluate safety and efficacy in the context of the specific clinical condition being treated. Early discussions with the Food and Drug Administration (FDA) and the National Cancer Institute (NCI) are recommended to identify prospectively the end points and trial designs needed to demonstrate effectiveness of a new drug. The general principles discussed will likely apply to the drug approval process for other medical disciplines as well.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. P. Rock, D. L. Kennedy, M. H. Furness, W. F. Pierce, R. Pazdur, and L. B. Burke Patient-Reported Outcomes Supporting Anticancer Product Approvals J. Clin. Oncol., November 10, 2007; 25(32): 5094 - 5099. [Abstract] [Full Text] [PDF]

				C. A. Meyers and P. D. Brown Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors J. Clin. Oncol., March 10, 2006; 24(8): 1305 - 1309. [Abstract] [Full Text] [PDF]

				Y. I. Garces, P. Yang, J. Parkinson, X. Zhao, J. A. Wampfler, J. O. Ebbert, and J. A. Sloan The Relationship Between Cigarette Smoking and Quality of Life After Lung Cancer Diagnosis Chest, December 1, 2004; 126(6): 1733 - 1741. [Abstract] [Full Text] [PDF]

				R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]

				C. A. Meyers and K. R. Hess Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression Neuro-oncol, April 1, 2003; 5(2): 89 - 95. [Abstract] [PDF]

				J. R. Johnson, G. Williams, and R. Pazdur End Points and United States Food and Drug Administration Approval of Oncology Drugs J. Clin. Oncol., April 1, 2003; 21(7): 1404 - 1411. [Abstract] [Full Text] [PDF]

				T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al. Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., May 15, 2002; 20(10): 2453 - 2463. [Abstract] [Full Text] [PDF]

				G. Vitale, P. Tagliaferri, M. Caraglia, E. Rampone, A. Ciccarelli, A. R. Bianco, A. Abbruzzese, and G. Lupoli Slow Release Lanreotide in Combination with Interferon-{alpha}2b in the Treatment of Symptomatic Advanced Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 983 - 988. [Abstract] [Full Text]